Freeline Therapeutics Holdings plc (FRLN)

NASDAQ: FRLN · IEX Real-Time Price · USD
0.450
-0.002 (-0.53%)
Mar 30, 2023, 11:19 AM EDT - Market open
-0.53%
Market Cap 28.91M
Revenue (ttm) n/a
Net Income (ttm) -100.67M
Shares Out 64.97M
EPS (ttm) -2.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 8,457
Open 0.460
Previous Close 0.452
Day's Range 0.431 - 0.460
52-Week Range 0.390 - 1.280
Beta 0.51
Analysts Buy
Price Target 5.10 (+1,033.33%)
Earnings Date Apr 4, 2023

About FRLN

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in Phase 1/2 clinical trial for the treatment of Fabry disease; and FLT201,... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Aug 7, 2020
Employees 235
Stock Exchange NASDAQ
Ticker Symbol FRLN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for FRLN stock is "Buy." The 12-month stock price forecast is $5.1, which is an increase of 1,033.33% from the latest price.

Price Target
$5.1
(1,033.33% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Freeline Therapeutics to Host Full Year 2022 Financial Results Call

LONDON, March 28, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, April 4, 2...

2 days ago - GlobeNewsWire

Freeline Announces Closing of Sale of Its CMC-Focused German Subsidiary

LONDON, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced the closing of the previously announced sale of its CMC-focused German subsidiary, Freeline ...

1 month ago - GlobeNewsWire

Freeline Reports January 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LONDON, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on January 31, 2023, the Company granted two newly hired employees non-statutory option...

1 month ago - GlobeNewsWire

Freeline Publishes Preclinical Proof-of-Concept Data for FLT190, its AAV Gene Therapy Candidate for Fabry Disease, in the Nature Journal Gene Therapy

Data show increased enzyme activity and reduction of harmful substrate, an established biomarker of efficacy in Fabry disease, in key tissues and organs

2 months ago - GlobeNewsWire

Freeline Reports December 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LONDON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on December 30, 2022, the Company granted four newly hired employees non-statutory opti...

2 months ago - GlobeNewsWire

Freeline Receives Approval to Transfer to Nasdaq Capital Market

LONDON, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced that it received approval from the Nasdaq Stock Market LLC (“N...

4 months ago - GlobeNewsWire

Freeline Reports Third Quarter 2022 Financial Results and Corporate Update

Entered into definitive agreement to sell CMC-focused German subsidiary and related IP for $25 million, while retaining rights to AAVS3 capsid and maintaining access to capabilities and technologies

4 months ago - GlobeNewsWire

Freeline to Present at the Stifel Healthcare Conference

LONDON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that Chief Executive Officer Michael Parini will participate in a fireside chat at the Stife...

5 months ago - GlobeNewsWire

Freeline Reports October 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LONDON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on October 31, 2022, the Company granted three newly hired employees non-statutory opti...

5 months ago - GlobeNewsWire

Freeline Announces September 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LONDON, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on September 30, 2022, the Company granted five newly hired employees non-statutory opt...

6 months ago - GlobeNewsWire

Freeline Initiates Dosing of Second Cohort in MARVEL-1 Trial of FLT190 Gene Therapy Candidate for People with Fabry Disease

LONDON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that the first patient has been dosed in the second dose cohort of the Phase 1/2 MARVEL-1 cl...

6 months ago - GlobeNewsWire

Freeline Announces August 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Freeline Announces Inducement Grants Freeline Announces Inducement Grants

7 months ago - GlobeNewsWire

Freeline Therapeutics Holdings PLC Sponsored ADR (FRLN) Could Find Support Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for Freeline Therapeutics Holdings PLC Sponsored ADR (FRLN), indicating that the stock has found support. This, combined with an ...

7 months ago - Zacks Investment Research

5 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

Let us look at some drug/biotech stocks, ABSI, AXLA, FRLN, DICE and PLRX, which are poised to beat on second-quarter earnings.

Other symbols: ABSIAXLADICEPLRX
8 months ago - Zacks Investment Research

Freeline Reports Second Quarter 2022 Financial Results and Business Highlights

Six patients dosed in B-LIEVE trial of FLT180a in hemophilia B in four months and initial and emerging cohort one data reported, followed by NEJM publication of B-AMAZE long-term data

8 months ago - GlobeNewsWire

Freeline Announces July 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LONDON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on July 29, 2022, the Company granted its newly hired Chief People Officer Nicole Jones...

8 months ago - GlobeNewsWire

Here's Why Freeline Therapeutics Holdings PLC Sponsored ADR (FRLN) Could be Great Choice for a Bottom Fisher

Freeline Therapeutics Holdings PLC Sponsored ADR (FRLN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical cha...

8 months ago - Zacks Investment Research

New England Journal of Medicine Publishes Positive Long-Term Data on Freeline's Gene Therapy Candidate FLT180a for People with Hemophilia B

Treatment with FLT180a led to durable expression of coagulation factor IX (FIX) and strong decreases in both bleeding rates and need for FIX replacement among patients Treatment with FLT180a led to du...

9 months ago - GlobeNewsWire

Freeline Therapeutics Holdings PLC Sponsored ADR (FRLN) Upgraded to Buy: Here's What You Should Know

Freeline Therapeutics Holdings PLC Sponsored ADR (FRLN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock highe...

9 months ago - Zacks Investment Research

Freeline Posts Cases Of Lower FIX Expression, Higher Liver Enzymes From Hemophilia Candidate

Freeline Therapeutics Holdings plc (NASDAQ: FRLN) announced the presentation of safety and initial efficacy data from the first cohort of the Phase 1/2 B-LIEVE trial for FLT180a for hemophilia B. As o...

9 months ago - Benzinga

Genespire appoints Dr. Sabah Sallah as Chief Medical Officer

Genespire appoint s Dr. Sabah Sallah as Chief Medical Officer

Other symbols: QURE
9 months ago - GlobeNewsWire

Freeline Announces June 2022 Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

LONDON, July 01, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on June 30, 2022, the Company granted a newly hired employee non-statutory options to p...

9 months ago - GlobeNewsWire

Freeline to Present New Clinical Data for FLT180a in Hemophilia B at International Society on Thrombosis and Haemostasis Congress

LONDON, June 24, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced the upcoming presentation of new and important clinical data for its AAVS3-based gene therap...

9 months ago - GlobeNewsWire

Freeline Initiates Dosing of Second Cohort in B-LIEVE Dose Confirmation Trial of FLT180a in Hemophilia B

Initial cohort one data suggest predictable and sustained Factor IX normalization, supporting additional dosing at the same low dose with the same optimized, prophylactic immune management regimen

10 months ago - GlobeNewsWire